ONX-0914: Selective Immunoproteasome Inhibitor for Autoim...
2026-01-20
ONX-0914 (PR-957) empowers researchers with robust, selective LMP7 inhibition—unlocking the study of cytokine modulation, immune regulation, and neuroinflammation in both cellular and animal models. Its high potency, solubility, and proven efficacy across arthritis, diabetes, and colitis models set it apart as a premier tool for dissecting immunoproteasome function and disease mechanisms.